Trial Wins Boost Eli Lilly In Cymbalta Cases As MDL Bid Looms
Eli Lilly & Co.'s third straight trial win over the withdrawal risks of its antidepressant Cymbalta sealed the company's success in persuading a federal jury that warnings on the drug were...To view the full article, register now.
Already a subscriber? Click here to view full article